Terminology Service for NFDI4Health
JSON

Cabazitaxel

Go to external page http://purl.obolibrary.org/obo/NCIT_C66937

A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB). [ ]

Term info

Label

Cabazitaxel

Synonyms
  • 1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate]
  • CABAZITAXEL
  • Cabazitaxel
  • Jevtana
  • RPR-116258A
  • Taxoid XRP6258
  • XRP-6258
  • cabazitaxel
  • taxoid XRP6258
Subsets

NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712

ALT DEFINITION

A drug used with prednisone to treat hormone-resistant prostate cancer that has spread and that had been treated with docetaxel. It is also being studied in the treatment of other types of cancer. Cabazitaxel blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent.

Accepted Therapeutic Use For

metastatic hormone-refractory prostate cancer

CAS Registry

183133-96-2

CHEBI ID

CHEBI:63584

Chemical Formula

C45H57NO14

Display Name

Cabazitaxel

FDA UNII Code

51F690397J

Has Target

http://purl.obolibrary.org/obo/NCIT_C17219

Preferred Name

Cabazitaxel

Semantic Type

Pharmacologic Substance, Organic Chemical

UMLS CUI

C2830183

code

C66937